DELC:CC - Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Driving the Psychedelic Conversation Forward Through Education Research and Service Delivery
- Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelics
- It seeks to achieve this through education, products and services, and research on psychedelics
- So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patients
- Delic recognizes the potential of psychedelics and their application in therapeutics, hence its investment in research, civic education, and service delivery in this sector
For many years, psychedelic drugs were frowned upon by society. This, along with psychedelics’ widespread popularity as recreational drugs in the 1960s and 70s, led to them being classified as a Schedule 1 controlled substance. Unfortunately, it only tainted their image further (https://ibn.fm/KukAl).
Fast forward to 2022, and the conversation around psychedelics is changing. Experts have highlighted the products’ usefulness beyond simply being recreational drugs. Most importantly, they have highlighted...
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at http://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.